Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Arvee Laboratories (India) Ltd (ARVEE)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 0 NSE: ARVEE Chemicals | Small Cap | Arvee Laboratories Share Price
BSE Share Price
Not Listed
Not Listed
Arvee Laboratories (India) Ltd (ARVEE)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 0 NSE: ARVEE Chemicals | Small Cap | Arvee Laboratories Share Price
BSE Share Price
Not Listed
Not Listed
Key Metrics
Valuation Multiples
Market Cap
₹235 Cr.
Current Price
₹0
52-Week Low / High
₹0 / 0
TTM EPS
-
TTM Sales
-
Book Value per Share
-
P/E Ratio
Industry PE
48
Price to Book (P/B)
Price to Sales (P/S)
EV/EBITDA
Dividend Yield
NAN%
Profitability Efficiency
Return on Equity (ROE)
%
Return on Capital Employed (ROCE)
%
Return on Assets (ROA)
%
Operating Profit Margin
0%
Net Profit Margin
-%
Gross Profit Margin
0%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
26.82%
Operating Profit Growth (1 Year)
-
-
Net Profit Growth (1 Year)
-
-
Asset Quality
Promoter Holding
73.50%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
-
Equity
₹11 Cr.
Face Value
₹10
All Time Low / High
₹0.00 / 0.00
Check Before You Invest
Quality
Not GoodValuation
Somewhat OvervaluedCheck Valuation charts
Price Trend
Strong
Is Arvee Laboratories (India) Ltd a good quality company?
Arvee Laboratories (India) Ltd is a weak quality company, based on a inconsistent multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Arvee Laboratories (India) Ltd performance compare with that of its Peers?
Revenue growth of Arvee Laboratories (India) Ltd vs industry peers?
Arvee Laboratories (India) Ltd revenue CAGR is %, compared to the industry median CAGR of 0%, indicating stable growth and maintaining its market share.
Promoter shareholding and pledge status of Arvee Laboratories (India) Ltd?
Promoters hold 73.50% of the Arvee Laboratories (India) Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of Arvee Laboratories (India) Ltd over the last decade?
Over the last 5 year(s), the stock has delivered a CAGR of 19.36% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Arvee Laboratories (India) Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good
Value Creation ⓘ
| Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 14.4% | 15.2% | 17.7% | 14.1% | 15.8% | 16% | 13.3% | 23.4% | 7% | 10% | - |
| Value Creation Index ⓘ | 0.0 | 0.1 | 0.3 | 0.0 | 0.1 | 0.1 | -0.1 | 0.7 | -0.5 | -0.3 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 26.8 | 34.4 | 47.8 | 54.9 | 45.4 | 47.4 | 40.3 | 61.4 | 30.4 | 38.5 | 41 |
| Sales YoY Gr. | - | 28.3% | 38.8% | 14.9% | -17.3% | 4.3% | -14.9% | 52.1% | -50.5% | 26.8% | - |
| Adj EPS ⓘ | 0.2 | 1.9 | 1 | 2.1 | 2 | 2.5 | 2.3 | 3 | 0.9 | 1.9 | 3.7 |
| YoY Gr. | - | 734.8% | -48.4% | 107.1% | -4.4% | 25% | -6.5% | 31.9% | -71.5% | 118.6% | - |
| BVPS (₹) ⓘ | 3.3 | 5.2 | 12.7 | 14.8 | 16.9 | 19.4 | 21.7 | 25.5 | 26.4 | 28.4 | 32.2 |
| Adj Net Profit ⓘ | 0.2 | 1.6 | 1.1 | 2.3 | 2.2 | 2.7 | 2.5 | 3.3 | 1 | 2.1 | 4 |
| Cash Flow from Ops. ⓘ | 6.2 | 4 | 6 | 9.5 | 10.3 | 1.7 | 4 | 2.9 | 3.7 | -0.2 | - |
| Debt/CF from Ops. ⓘ | 4.1 | 6.2 | 2.7 | 1.4 | 0.4 | 5.2 | 0.8 | 0.3 | 0.3 | -5 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 4.1% | -3.3% | -1.5% | 26.8% | ||||
| Adj EPS ⓘ | 26.3% | -0.8% | -6.4% | 118.6% | ||||
| BVPSⓘ | 27.2% | 10.9% | 9.3% | 7.4% | ||||
| Share Price | - | 18.8% | 21.2% | 28.9% | ||||
Key Financial Parameters ⓘ
| Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 9.2 | 45.4 | 11.8 | 14.8 | 12.2 | 13.4 | 11.1 | 12.8 | 3.3 | 6.9 | 12.1 |
| Op. Profit Mgn % ⓘ | 17.5 | 16.3 | 15 | 11.3 | 13.3 | 12.8 | 14 | 11.9 | 9.7 | 9.4 | 13 |
| Net Profit Mgn % ⓘ | 0.7 | 4.5 | 2.3 | 4.1 | 4.7 | 5.7 | 6.3 | 5.4 | 3.1 | 5.4 | 9.8 |
| Debt to Equity ⓘ | 9.6 | 6 | 1.2 | 0.8 | 0.2 | 0.4 | 0.1 | 0 | 0 | 0 | - |
| Working Cap Days ⓘ | 187 | 182 | 167 | 140 | 124 | 123 | 167 | 127 | 271 | 181 | 210 |
| Cash Conv. Cycle ⓘ | 70 | 83 | 64 | 53 | 33 | 25 | 53 | 43 | 85 | 66 | 149 |
Valuation of Arvee Laboratories - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
No data found!
No data found!
No data found!
No data found!
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Arvee Laboratories (India) Ltd FAQs
The current trading price of Arvee Laboratories on 01-Jan-1970 05:30 is ₹0.00.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of Arvee Laboratories stood at ₹234.9 Cr
The latest P/E ratio of Arvee Laboratories as of 31-Dec-1969 is 58.04.
The latest P/B ratio of Arvee Laboratories as of 31-Dec-1969 is 6.62.
The 52-week high of Arvee Laboratories is ₹0.00 and the 52-week low is ₹0.00.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Arvee Laboratories is ₹41.26 ( Cr.) .
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Arvee Laboratories (India) Ltd is a below average quality company.
The key valuation ratios of Arvee Laboratories (India) Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Arvee Laboratories (India) Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing
About Arvee Laboratories (India) Ltd
Arvee Laboratories (India) (Arvee) started its operations with an aim to become a leader & frontrunner in chemical industry by providing the best and innovative quality chemical products. The company intended to establish eco-friendly organization dedicated to providing good quality innovative products at very competitive price. Keeping quality and precision as the benchmark for any operation, Arvee hails to become the most sought-after chemical manufacturing company offering best products at very reasonable price. Quality, Service and Advancement are the mainstay of the company which has brought it this far in the chemical industry. From humble beginnings, Arvee has carved a remarkable presence in the chemical industry in a very short span.
Ever since inception, quality has been a constant and guiding factor in every practice at Arvee. More than a practice it is a pledge taken by each and every member of its team to stay committed and true to the highest quality standards. This enables the company to manufacture best quality products while taking care of safekeeping the environment and personnel. Over the years, its commitment to maintaining high quality standards in an eco-friendly way has helped it to build long-lasting and rewarding relationships with its clients. As part of the quality policy, every process and practice at Arvee is committed to greater cause of keeping the environment safe and sustainable.
The company was incorporated as ‘Arvee Laboratories (India) Private Limited’ under the provisions of the Companies Act, 1956 vide certificate of incorporation dated January 27, 2012 in Ahmedabad, Gujarat. Subsequently, the name of the company was changed to ‘Arvee Laboratories (India) Limited’ pursuant to shareholder’s resolution on September 11, 2017 and vide fresh certificate of incorporation dated September 19, 2017.
Business area of the company
Arvee is engaged in manufacturing of specialized chemicals. The plant facilities and other utility services at Arvee are equipped to undertake a host of processes namely, Nitration, Sulfonation, Reduction, Halogenation, Esterification, Alkylation, Acylation, Hoffman Reaction, Grignard Reaction, Vilsmeyer Heack Reaction, Sandmeyer Reaction, Caustic Fusion, Friedel-Crafts Reaction and Catalytic Reduction. The company caters to the demand of both domestic as well as international markets.
Products
Polymer Modifiers
- Dimethyl 5-Sodiosulfoisophthalate
- 5-Sulfoisophthalic Acid Mono Sodium Salt
- 5-Sulfoisophthalic Acid Mono Lithium Salt
- 5-Sodiosulfo-Bis-(β-Hydroxyethyl)-Isophthalate
Contrast Media Intermediates
- 5-Nitroisophthalic acid
- Dimethyl 5-Nitroisophthalate
- Monomethyl 5-Nitroisophthalate
- 5-Hydroxyisophthalic acid
- 5-Aminoisophthalic acid
- Dimethyl 5-Aminoisophthalate
- 3,5-Dinitrobenzoic Acid
- 3,5-Diamino Benzoic Acid
Drug Intermediates
- 2-Acetyl Thiophene
- Thiophene-2-Carboxaldehyde
- 4-Amino Pyridine
- 2-Chloro-5-nitrobenzoic acid
Major Events and Milestones:
- 2012: The company was incorporated as Arvee Laboratories (India) Private Limited.
- 2013: Acquired land, building and machineries from Skylink Chemicals Private Limited and started manufacturing unit.
- 2013: Started construction of its first plant for Thiophene Derivatives.
- 2013: Completes construction and commissioning of its Thiophene Derivatives Plant.
- 2014: Plant inspected and approved by leading India pharmaceutical manufacturer for supply of Thiophene Derivatives.
- 2014: Started construction of plant for Sulfo and Nitro Derivatives of Isophthalic Acid.
- 2014: Received ISO 9001:2008 accreditation for NABCB and DAKKS from TUV NORD.
- 2014: Plant inspected and approved by an American X-Ray Contrast Media manufacturer and started pilot trials with the manufacturer.
- 2014: Plant inspected and approved by a European X-Ray Contrast Media manufacturer and started pilot trials with the manufacturer.
- 2015: Completed construction and commissioning of plant for Nitro Derivatives of Isophthalic Acid.
- 2015: After receiving inspection approval, the Company gets order for yearly supply of Nitro Derivatives of Isophthalic Acid to leading contrast media manufacturer in the United States of America.
- 2015: Export to United States of America (USA) started.
- 2015: Plant inspected and approved by European manufacturer for supply of Thiophene Derivatives.
- 2015: Export of Thiophene Derivatives started to Europe.
- 2016: Receives internal approvals for their Nitro Derivatives of Isophthalic acid from leading X- Ray contrast media manufacturer in Europe.
- 2016: Receive approval for the Sulfo Derivatives of Isophthalic acid from a large polymer manufacturer in the United States of America and received yearly order for supply of Sulfo Derivatives to the USA.
- 2016: Crossed turnover of Rs 25 crores.
- 2017: Plant inspected and approved by an American X-ray contrast media manufacturer who has the largest market share in the world and started of pilot trials with the manufacturer.
- 2017: Received order for commercial trials of Nitro Derivatives of Isophthalic acid from the largest manufacturer of X-ray contrast media manufacturer in the world.
- 2017: The name of the company was changed to Arvee Laboratories (India) Limited pursuant to conversion into a public limited company.
- 2021: Sold its 100% investment in its subsidiary company namely ‘Arvee Speciality Chemicals’ and ceased to be subsidiary of company.
You have 48 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
